FDA Expands Blinatumomab Approval for ALL to Include MRD


The US Food and Drug Administration has approved blinatumomab (Blincyto) for patients in remission from B-cell precursor ALL with MRD.

The US Food and Drug Administration (FDA) has approved blinatumomab (Blincyto) to treat patients in remission from B-cell precursor acute lymphoblastic leukemia (ALL) with minimal residual disease (MRD). "This is the first FDA-approved treatment for patients with MRD-positive ALL," said Richard Pazdur, MD, in a press release. "Because patients who have MRD are more likely to relapse, having a treatment option that eliminates even very low amounts of residual leukemia cells may help keep the cancer in remission longer." Dr. Pazdur is director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.

Blinatumomab is a BiTE-class (bispecific T-cell engagers) monoclonal antibody. It works by attaching to CD19 protein on leukemia cells and CD3 protein found on certain immune system cells. Bringing these immune cells close to the leukemia cells improves the ability of the immune cells to attack the leukemia cells.

The effectiveness of blinatumomab in MRD-positive ALL was shown during a single-arm trial of 86 patients, all in their first or second remission with detectable MRD in at least 1 out of 1,000 bone marrow cells. Clinical efficacy was based on both the achievement of undetectable MRD using a test that could detect at least 1 cancer cell in 10,000 after 1 cycle of blinatumomab, and the duration of remission. Undetectable MRD was achieved by 70 patients, with more than half of the patients remaining alive and in remission for a minimum of 22.3 months.

Side effects of blinatumomab when used to treat MRD-positive B-cell precursor ALL include infections, fever, headache, infusion-related reactions, low WBC count, febrile neutropenia, and low platelet levels. There is also a risk of adverse reactions in pediatric patients due to the benzyl alcohol preservative used for infusion of blinatumomab. The drug should be prepared with preservative free-saline for use in patients weighing less than 48 pounds.

Related Videos
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Related Content